SAFETY, TOLERABILITY AND PHARMACOKINETICS OF EVINACUMAB, AN ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3) INHIBITOR, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS

被引：0
|
作者：
Harada-Shiba, M. [1 ]
Ali, S. [2 ]
Gipe, D. A. [2 ]
Gasparino, E. [3 ]
Son, V. [4 ]
Pordy, R. [2 ]
Catapano, A. L. [5 ]
机构：
[1] Natl Cerebral & Cardiovasc Ctr, Mol Innovat Lipidol, Suita, Osaka, Japan
[2] Regeneron Pharmaceut Inc, Cardiovasc & Metab Therapeut, New York, NY USA
[3] Regeneron Pharmaceut Inc, Therapeut Area Program Management, New York, NY USA
[4] Regeneron Pharmaceut Inc, Biostat & Data Management, New York, NY USA
[5] IRCCS MultiMed, Irccs Multimed Sesto S Giovanni, Milan, Italy
来源：
ATHEROSCLEROSIS | 2020年 / 315卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1333
引用
收藏
页码：E36 / E37
页数：2
相关论文
共 50 条
  • [1] A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects
    Harada-Shiba, Mariko
    Ali, Shazia
    Gipe, Daniel A.
    Gasparino, Evelyn
    Son, Vladimir
    Zhang, Yi
    Pordy, Robert
    Catapano, Alberico L.
    [J]. ATHEROSCLEROSIS, 2020, 314 : 33 - 40
  • [2] EVALUATING THE EFFECT OF LIPID-APHERESIS ON EVINACUMAB AND ANGIOPOIETIN-LIKE 3 (ANGPTL3) LEVELS
    Moriarty, P. M.
    Dutton, J. -A.
    Gorby, L.
    Vance, J.
    Ali, S.
    Zhao, A.
    Khilla, N.
    Alejandro, M.
    Rodriguez, J.
    Rajadhyaksha, M.
    Andisik, M.
    Gipe, D. A.
    Zhang, Y.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E37 - E37
  • [3] Atypical angiopoietin-like protein that regulates ANGPTL3
    Quagliarini, Fabiana
    Wang, Yan
    Kozlitina, Julia
    Grishin, Nick V.
    Hyde, Rhonda
    Boerwinkle, Eric
    Valenzuela, David M.
    Murphy, Andrew J.
    Cohen, Jonathan C.
    Hobbs, Helen H.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (48) : 19751 - 19756
  • [4] Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
    Lu, Xinjie
    [J]. CURRENT MEDICINAL CHEMISTRY, 2020, 27 (31) : 5159 - 5174
  • [5] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
    Tarugi, Patrizia
    Bertolini, Stefano
    Calandra, Sebastiano
    [J]. JOURNAL OF BIOMEDICAL RESEARCH, 2019, 33 (02): : 73 - 81
  • [6] Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
    Chen, Pei-Yi
    Gao, Wan-Yun
    Liou, Je-Wen
    Lin, Ching-Yen
    Wu, Ming-Jiuan
    Yen, Jui-Hung
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)
  • [7] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
    Patrizia Tarugi
    Stefano Bertolini
    Sebastiano Calandra
    [J]. The Journal of Biomedical Research, 2019, 33 (02) : 73 - 81
  • [8] Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
    Kosmas, Constantine E.
    Bousvarou, Maria
    Sourlas, Andreas
    Papakonstantinou, Evangelia J.
    Genao, Edilberto Pella
    Uceta, Rogers Echavarria
    Guzman, Eliscer
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2022, 14 : 49 - 59
  • [9] Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia
    Shoji, Tetsuo
    Hatsuda, Sawako
    Tsuchikura, Shoko
    Kimoto, Eiji
    Kakiya, Ryusuke
    Tahara, Hideki
    Koyama, Hidenori
    Emoto, Masanori
    Tabata, Tsutomu
    Nishizawa, Yoshiki
    [J]. ATHEROSCLEROSIS, 2009, 207 (02) : 579 - 584
  • [10] Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome
    Vatannejad, Akram
    Salimi, Fouzieh
    Moradi, Nariman
    Fouani, Fatima Zahraa
    Zandieh, Zahra
    Ansaripour, Soheila
    Sadeghi, Asie
    Fadaei, Reza
    [J]. LIFE SCIENCES, 2020, 263
12345